Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal
Executive Summary
Arrowhead Pharmaceuticals shifts focus to subcutaneous platform after abandoning lead hepatitis B program and related products due to toxicity concerns, resolving to lay off 30% of staff.
You may also be interested in...
J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B
The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.
RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.